Anna Kaletka
Papers
1
Total Citations
7
H-Index
1
About
Anna Kaletka is a clinical researcher whose work focuses on advancing radiotherapy techniques for prostate cancer, particularly through the use of robotic ultrahypofractionated stereotactic body radiotherapy. Her most cited study, a prospective evaluation of CyberKnife™-based fractionated stereotactic radiotherapy in 132 men with low- and intermediate-risk prostate cancer, demonstrated that a total dose of 36.25 Gy delivered in five fractions is associated with manageable acute toxicity. This work contributes to the growing body of evidence supporting ultrahypofractionation as a safe, effective, and convenient treatment option, reducing overall treatment time while maintaining tumor control. With 7 citations, her research has informed clinical protocols and helped validate the role of robotic radiosurgery in prostate cancer management. Kaletka’s contributions are particularly valuable for radiation oncologists and medical physicists seeking to optimize dose delivery and minimize side effects. Her findings underscore the potential of non-invasive, high-precision radiotherapy to improve patient quality of life, marking her as a dedicated investigator in the evolving landscape of prostate cancer therapeutics.
Research Focus
Key Achievements
Top Papers
- 1